亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

265 CD47xPD-L1 bispecific antibodies for cancer therapy

作者
Xavier Chauchet,Elise Pernarrieta,Nicolas Bosson,Sébastien Calloud,Louis Hellequin,Margaux Legrand,Alizée Viandier,Françoise Richard,Laura Cons,Pauline Malinge,Tereza Bautzová,Jérémie Bourguignon,Guillemette Pontini,Mengzhu Sun,Ulla Ravn,Valéry Moine,Yves Poitevin,Stéphanie Hugues,Nicolas Fischer,Limin Shang
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:: A287-A287 被引量:1
标识
DOI:10.1136/jitc-2021-sitc2021.265
摘要

Background PD-1/PD-L1 blockade can significantly improve survival across many types of cancer, but only in a minority of patients. To broaden its therapeutic efficacy, several combination partners are now being evaluated together with PD-1/PD-L1 blockade. Agents blocking CD47/SIRPα innate immune checkpoint are one such example, and co-targeting PD-1/PD-L1 and CD47 with monoclonal antibody (mAb) combinations showed increased antitumor responses in preclinical studies. However, CD47 mAbs are hindered by ubiquitous CD47 expression leading to rapid target-mediated clearance and safety concerns. Consequently, dual-targeting CD47xPD-L1 bispecific antibodies (bsAbs) enabling preferential inhibition of CD47 on PD-L1-positive cells are being tested as an alternative approach. We compare here two distinct bsAbs, based on a common PD-L1 antibody arm, with differing FcgR-enabling effector functions and CD47-binding arm affinities. Methods An array of fully human bsAbs associating a high affinity PD-L1 arm to CD47 arms with varying affinities were generated using the κλ-body platform.1 CD47xPD-L1 bsAbs of human IgG1 isotype (CD47 low affinities) or IgG4 isotype (CD47 high affinities) were screened in various binding assays (including to red blood cells (RBC)) and in receptor-blocking assays, and then tested for their Fc-mediated killing and T-cell activation activity (SEA-stimulated PBMC assay). Selected molecules were evaluated in vivo. Results Both bsAb approaches demonstrated strong blockade of PD-1/PD-L1 interaction and significantly enhanced T-cell activation in vitro. CD47lowxPD-L1 IgG1 bsAbs did not bind to RBC and showed PD-L1-guided inhibition of CD47. ADCP and ADCC experiments with a panel of tumor cell lines expressing various target levels showed superior killing activity with CD47lowxPD-L1 IgG1 bsAbs as compared to the anti-PD-L1 IgG1 mAb, avelumab. On the other hand, CD47highxPD-L1 IgG4 bsAbs showed residual RBC binding and PD-L1-independent blocking of CD47/SIRPα. These CD47high IgG4 bsAbs were able to enhance the anti-tumor activity of anti-tumor-associated antigen (TAA) mAbs in vitro (phagocytosis), and in vivo (Raji lymphoma xenograft model). In addition, anti-tumor activity of mouse CD47xPD-L1 bsAbs in a syngeneic MC38 colon carcinoma model was demonstrated. Conclusions With the objective of finding the optimal CD47xPD-L1 bsAb design, two approaches targeting CD47 and PD-L1 inhibition were tested. Both the CD47lowxPD-L1 IgG1 bsAbs and CD47highxPD-L1 IgG4 bsAbs were able to mediate enhanced antitumor responses, the former as a standalone treatment, the latter in conjunction with an anti-TAA mAb. To further characterize the CD47lowxPD-L1 and CD47highxPD-L1 bsAbs, lead candidates will be tested in PK and tolerability studies in non-human primates. References Fischer N, Elson G, Magistrelli G, Dheilly E, Fouque N, Laurendon A, et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun 2015 May;6(1):6113.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.3的应助被u264877采纳,获得10
1秒前
机智的白卉的应助被u102060采纳,获得10
6秒前
李健的应助被u680513采纳,获得10
8秒前
优雅谷蕊完成签到,获得积分10
12秒前
odd完成签到,获得积分10
15秒前
科研通AI6.2的应助被u102060采纳,获得10
16秒前
余凌兰完成签到 ,获得积分10
16秒前
syvshc的应助被u680513采纳,获得10
18秒前
领导范儿的应助被u855744采纳,获得10
20秒前
超级的迎梅完成签到,获得积分10
32秒前
机智的白卉的应助被u680513采纳,获得10
34秒前
科研通AI6.3的应助被u680513采纳,获得10
38秒前
小蘑菇的应助被吴彦祖采纳,获得10
42秒前
46秒前
科研通AI6.4的应助被u855744采纳,获得10
52秒前
科研通AI6.3的应助被u855744采纳,获得10
54秒前
科研通AI6.3的应助被u264877采纳,获得10
54秒前
科研通AI6.2的应助被u855744采纳,获得10
56秒前
科研通AI6.3的应助被u855744采纳,获得10
56秒前
科研通AI6.2的应助被u264877采纳,获得10
59秒前
科研通AI6.3的应助被u264877采纳,获得10
1分钟前
风吹麦浪的应助被u583484采纳,获得10
1分钟前
科研通AI6.3的应助被u264877采纳,获得10
1分钟前
漂亮的新梅完成签到,获得积分10
1分钟前
七七完成签到 ,获得积分10
1分钟前
忧郁的数据线关注了科研通微信公众号
1分钟前
1分钟前
syvshc的应助被u721406采纳,获得10
1分钟前
u588294驳回了852的应助
1分钟前
1分钟前
1分钟前
遇上就这样吧给u266829的求助进行了留言
1分钟前
顺利手链完成签到,获得积分10
1分钟前
生动的昊焱完成签到,获得积分10
1分钟前
阿切尔代的应助被科研通管家采纳,获得10
1分钟前
1分钟前
2分钟前
吴彦祖发布了新的文献求助10
2分钟前
大胆醉卉完成签到,获得积分10
2分钟前
吴彦祖完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185144
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834129
捐赠科研通 7782640
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558762
邀请新用户注册赠送积分活动 2481206